雷尼替丁的临床药物动力学。

文章的细节

引用

复制到剪贴板

罗伯茨CJ

雷尼替丁的临床药物动力学。

May-Jun Pharmacokinet。1984; 9(3): 211 - 21所示。doi: 10.2165 / 00003088-198409030-00003。

PubMed ID

6329583 (在PubMed

]

文摘

可用的方法分析雷尼替丁在血浆和尿液中药物及其代谢物是高效液相色谱法和放射免疫检定法。口服后,在正常个体雷尼替丁的吸收迅速被发现,血浆浓度峰值出现在1到3个小时。血浆浓度峰值熊一个常数与剂量的关系,但个体间差异很大。雷尼替丁口服后的生物利用度约有50%是由于presystemic肝的新陈代谢。血浆蛋白结合的雷尼替丁大约是15%,表观分布容积大于身体体积。雷尼替丁穿透很差到脑脊液但集中到母乳。通过静脉注射后,血浆浓度衰减biexponential的方式。消除半衰期几乎是口服后2小时有点长。等离子体间隙约为600毫升/分钟的大多数是肾清除率。消除雷尼替丁不存在剂量依赖的相关性。 Hepatic metabolism is the other major route of elimination and there may be some enterohepatic recycling of the drug. Food has no effect on the kinetics of ranitidine but concurrent administration of antacids reduces its absorption. Renal disease causes an increase in ranitidine plasma concentrations through reduced clearance and possibly increased bioavailability. Chronic liver and some reduction in clearance. In the elderly, there is a reduction in clearance and prolongation of the elimination half-life but little effect on bioavailability. There is a relationship between plasma concentrations of ranitidine and suppression of gastric acid production but wide interindividual variability.

DrugBank数据引用了这篇文章

药物

雷尼替丁